Innate Pharma (NASDAQ:IPHA) Shares Up 1.5% - Time to Buy?

Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was up 1.5% during trading on Friday . The company traded as high as $1.99 and last traded at $1.97. Approximately 4,306 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 183,983 shares. The stock had previously closed at $1.94.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and set a $11.50 target price on shares of Innate Pharma in a research note on Friday, March 28th.

Innate Pharma Trading Up 5.9 %

The company has a fifty day moving average of $1.99 and a two-hundred day moving average of $1.89.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.